What is the 13F Pro Quality Score for CRSP?

13F Pro ranks CRISPR Therapeutics AG (CRSP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRSP's current score at https://13fpro.ai/research/CRSP (free sign-up required for the full ranking).

Which hedge funds own the most CRSP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRSP include ARK Investment Management, BlackRock,, Orbis Allan Gray Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRSP as soon as new 13F filings post.

Where does 13F Pro source CRSP data?

All CRISPR Therapeutics AG fundamentals and ownership data come directly from SEC EDGAR. CRISPR Therapeutics AG files with the SEC under CIK 1674416. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRSP in?

CRISPR Therapeutics AG (CRSP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRSP research updated on 13F Pro?

CRSP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CRISPR Therapeutics AG(CRSP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1674416 CRSP stock profile & AI dashboard →

13F Pro Quality Score

4.5/100

Rank #2,853 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.2/100

Profitability

0.5/100

Balance Sheet

9.1/100

Earnings Quality

30.0/100

Free Cash Flow

0.5/100

Institutional Flow

23.0/100

Revenue Scale

1.9/100

Dilution Risk

0.4/100

CRSP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CRISPR Therapeutics AG (CRSP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRSP at 4.5/100 on a 32-signal composite quality model, placing it at rank #2,853 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.2) and profitability (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CRISPR Therapeutics AG reports quarterly revenue of $1.5M, net income of $-122.9M, free cash flow of $-109.4M. Top institutional holders of CRSP by reported 13-F value include ARK Investment Management, BlackRock,, Orbis Allan Gray Ltd, based on the most recent SEC filings. CRSP trades on the Nasdaq exchange and files with the SEC under CIK 1674416. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRISPR Therapeutics AG directly from SEC EDGAR. CRISPR Therapeutics AG's 13F Pro composite quality score has ranged between 4 and 6 since 2026, currently 4.5 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about CRISPR Therapeutics AG

Quirks, history, and lore behind CRSP — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · Swiss-domiciled · listed on Nasdaq · focused on developing transformative medicines for serious diseases.
2
The Numbers
Minimal product revenue for most of its history — it has operated largely on collaboration payments and milestones — though a landmark approval brought in hundreds of millions in its first commercial year.
3
The History
Founded in 2013, just months after the core technology it's built on was published in a landmark scientific paper — it was essentially incorporated alongside the hype.
4
The Secret
Its key partner is Vertex Pharmaceuticals, with whom it co-developed a therapy for sickle cell disease and beta thalassemia — two conditions with very few prior curative options.
5
The Lore
The technology it uses won its pioneers the Nobel Prize in Chemistry in 2020 — making this one of the few public companies whose entire platform is built on a Nobel-winning discovery.
6
The Giveaway
Its name is literally the technology: gene-editing scissors that cut DNA at precise locations — and yes, the ticker even spells it out.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.5M

Net Income

Q1 2026

$-122.9M

Free Cash Flow

Q1 2026

$-109.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-90.6% YoY

$3.5MFY 2025

FY22 $1.2MFY23 $371.2MFY24 $37.3MFY25 $3.5M

Net Income

-58.8% YoY

$-581.6MFY 2025

FY22 $-650.2MFY23 $-153.6MFY24 $-366.3MFY25 $-581.6M

Operating Income

-42.4% YoY

$-664.6MFY 2025

FY22 $-673.2MFY23 $-222.5MFY24 $-466.6MFY25 $-664.6M

EPS (Diluted)

-49.1% YoY

$-6.47FY 2025

FY22 $-8.36FY23 $-1.94FY24 $-4.34FY25 $-6.47

Total Assets

+1.0% YoY

$2.27BFY 2025

FY22 $2.24BFY23 $2.23BFY24 $2.24BFY25 $2.27B

Total Debt

$0.00FY 2025

FY22 —FY23 —FY24 —FY25 $0.00

Op. Cash Flow

-141.7% YoY

$-345.0MFY 2025

FY22 $-495.7MFY23 $-260.4MFY24 $-142.8MFY25 $-345.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.5M -90.6%	$37.3M -89.9%	$371.2M +30885.5%	$1.2M -99.9%	$915.0M +127154.9%	$719.0K
Net Income	$-581.6M -58.8%	$-366.3M -138.4%	$-153.6M +76.4%	$-650.2M -272.2%	$377.7M +208.3%	$-348.9M
Operating Income	$-664.6M -42.4%	$-466.6M -109.7%	$-222.5M +66.9%	$-673.2M -280.2%	$373.5M +205.4%	$-354.4M
EPS (Diluted)	$-6.47 -49.1%	$-4.34 -123.7%	$-1.94 +76.8%	$-8.36 -277.9%	$4.70 +188.8%	$-5.29
Total Assets	$2.27B +1.0%	$2.24B +0.6%	$2.23B -0.6%	$2.24B -18.5%	$2.75B +50.5%	$1.83B
Total Debt	$0.00	—	—	—	—	—
Operating Cash Flow	$-345.0M -141.7%	$-142.8M +45.2%	$-260.4M +47.5%	$-495.7M -192.0%	$539.0M +326.1%	$-238.4M

AI Insight: CRSP Financial Trends

CRISPR Therapeutics burned through $109M in operating cash flow in Q1 2026 while absorbing $585M in new debt, marking a sharp balance-sheet deterioration.

• Revenue has been flat at $1M for seven of eight quarters; Q4 2024's $36M was a one-time event, not a trend.

• Operating losses widened from $-110M in Q3 2024 to $-229M in Q2 2025 before partially recovering to $-130M in Q1 2026.

• Equity eroded from $1,981M in Q2 2024 to $1,815M in Q1 2026, a $166M decline over six quarters.

• $585M in total debt appeared for the first time in Q1 2026, where no debt existed in any prior quarter shown.

⚠ The sudden $585M debt load in Q1 2026 with no prior leverage raises questions about runway and capital structure strategy.

⚠ Operating cash outflow hit $-109M in Q1 2026 — the worst since Q2 2025 — monitor whether burn rate stabilizes.

⚠ Q4 2024's $36M revenue spike was not repeated; any recurring collaboration or royalty milestone is a key inflection to track.

AI Insight: CRSP Ratio Trends

CRISPR Therapeutics remains deeply unprofitable with no margin data visible outside Q4 2024's severe -181% operating margin.

• ROE improved from -48.8% in Q2 2025 to -27.1% in Q1 2026, suggesting reduced quarterly loss intensity.

• ROIC swung from -53.6% in Q2 2025 to -21.7% in Q1 2026, the least negative reading in the visible quarterly series.

• ROA on a TTM basis stands at -20.9%, broadly consistent with the -18% to -25% range seen across most quarters.

⚠ Q4 2024's -181% operating margin and -104.5% NPM signal a severe one-period cost spike — recurrence would be damaging.

⚠ D/E of 0.32 (only available for TTM and Q1 2026) warrants monitoring as cash burn continues with no visible profitability.

⚠ Persistent negative ROIC across all quarters indicates capital destruction; a path to positive returns remains unclear.

Get alerted when CRSP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CRISPR Therapeutics AG including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRSP

ARK Investment Management LLC
$538.2M11,313,623 sh
BlackRock, Inc.
$365.3M7,680,073 sh
Orbis Allan Gray Ltd
$290.5M6,106,011 sh
Capital World Investors
$224.8M4,725,037 sh
STATE STREET CORP
$189.4M3,982,500 sh
GSK plc
$153.2M3,220,627 sh
GEODE CAPITAL MANAGEMENT, LLC
$113.1M2,377,164 sh
SR ONE CAPITAL MANAGEMENT, LP
$97.0M2,038,763 sh
FMR LLC
$93.0M1,954,694 sh
Nikko Asset Management Americas, Inc.
$88.2M1,853,875 sh

Fund	Value	Shares
ARK Investment Management LLC	$538.2M	11,313,623
BlackRock, Inc.	$365.3M	7,680,073
Orbis Allan Gray Ltd	$290.5M	6,106,011
Capital World Investors	$224.8M	4,725,037
STATE STREET CORP	$189.4M	3,982,500
GSK plc	$153.2M	3,220,627
GEODE CAPITAL MANAGEMENT, LLC	$113.1M	2,377,164
SR ONE CAPITAL MANAGEMENT, LP	$97.0M	2,038,763
FMR LLC	$93.0M	1,954,694
Nikko Asset Management Americas, Inc.	$88.2M	1,853,875

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRSP on your watchlist

Track score changes the day CRISPR Therapeutics AG files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRSP a good stock to buy?

13F Pro's AI-powered analysis of CRISPR Therapeutics AG (CRSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRSP are available on the CRSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRSP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CRISPR Therapeutics AG's investment landscape.